US FDA to lift Import alert imposed on Divis Lab’s Visakhapatnam facility
DSIJ Intelligence / 10 Jul 2017
US FDA has issued import alert for violation of good manufacturing practices, but exempted 10 products, including drugs to treat epilepsy, cancer and HIV.
that The US Food & Drug Administration (USFDA) will lift the import alert 99-32 imposed on Divis Lab Unit-II at Visakhapatnam, the company on Monday informed.
On March 2017, US FDA has issued import alert for violation of good manufacturing practices, but exempted 10 products, including drugs to treat epilepsy, cancer and HIV. The import alert means products manufactured in the unit will not be allowed to be marketed in the US.
The company also received a warning letter and on May 2017 for Visakhapatnam facility.
Meanwhile, at Rs 782.00 per share, the stock on BSE surged 14.97%.The stock attracted a total traded quantity of 21.84 lakh.
As per market observers, the company has a return of equity of 27.43% for 3 years. The company has also been maintaining a dividend payout of 29.00%.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.